Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$9.06M$9.06Mderived−11.9% vs Q4 2018 Net Income-$2.53M-$2.53MderivedN/M vs Q4 2018 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$1,729,130−9.3% Operating Incomederived-$1,985,096N/M Operating Cash Flowderived-$478,837N/M Margins · derivedGross margin19.1%+0.5 pt vs Q4 2018
Operating margin-21.9%+84.4 pt vs Q4 2018
Net margin-27.9%+164.3 pt vs Q4 2018
ended Dec 31, 2019 · filed Mar 25, 2020 · 85 d after period end